Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Ductal Adenocarcinoma 1Neuroendocrine Tumors 1Neoplasms 1Myocarditis 1Hematologic Neoplasms 1

Interventions

pembrolizumab 20Bevacizumab 14Carboplatin 12Standard of Care 10Nivolumab 9Cyclophosphamide 9Cetuximab 8Pemetrexed 7Exercise 7Doxorubicin 7durvalumab 6atezolizumab 6Temozolomide 6Radiotherapy 6Prednisone 6Paclitaxel 6Cisplatin 6Blood Specimen Collection 6abemaciclib 5Fluorouracil 5130-nm albumin-bound paclitaxel 5olaparib 4dostarlimab 4Rituximab 4Leucovorin 4Gemcitabine 4Fulvestrant 4Docetaxel 4Dexamethasone 4venetoclax 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Positron Emission Tomography Computed Tomography × 30 days × Clear all
NCT05513027 2026-05-08

Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection

Washington University School of Medicine

Phase NA Terminated
11 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡